Close Menu

NEW YORK – Biomedical software company BostonGene said on Tuesday that it is collaborating with the Dana-Farber Cancer Institute's Weinstock Laboratory to research treatment response and resistance among patients with T-cell lymphomas.

Specifically, the partnership will focus on uncovering mechanisms that might cause patients' response or resistance to PI3 kinase inhibitors, including duvelisib (Verastem Oncology's Copiktra). Causes of adverse effects of duvelisib in patients with T-cell lymphomas will also be part of the collaboration.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sep
23
Sponsored by
Beckman Coulter

This webinar will discuss a streamlined library preparation method for next-generation sequencing (NGS) that improves quality control testing capability while reducing the total number of steps compared to conventional multiplexed library workflows.

Sep
24
Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.